Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. (August 2016)

• Record Type: Journal Article
• Authors: Sattui, Sebastian E.; Gaffo, Angelo L.
• Is Part Of: Therapeutic advances in musculoskeletal disease. Volume 8:Number 4(2016:Aug.)
• Page Start: 145
• Page End: 159
• Publication Date: 2016-08
• Subjects: arhalofenate -- gout -- hyperuricemia -- lesinurad -- ulodesine -- URAT1 -- urate-lowering therapy; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; 616.7
• DOI: 10.1177/1759720X16646703
• Languages: English
• ISSNs: 1759-720X

Abstract

Despite being the most common type of inflammatory arthritis, gout is often poorly managed. Except for febuxostat and pegloticase, research in new therapeutic agents for the management of hyperuricemia in gout remained insufficient for several decades. With emerging evidence of possible roles of hyperuricemia in cardiometabolic comorbidities, as well as more convincing evidence regarding poor outcomes (e.g. disability, recurrent hospital admissions) in patients with uncontrolled gout, several agents are current under development. Increasing knowledge regarding renal urate transporters has resulted in the development of new generation uricosurics such as lesinurad and arhalofenate. This review aims at discussing current therapeutic strategies for gout, as well as their limitations and the possible role of emerging agents in the chronic management of hyperuricemia in gout. Drugs in phases I and II of development will be discussed, along with new agents and therapeutic classes, such as purine nucleoside phosphorylase inhibitors and dual-action drugs. These new developments are encouraging, and will hopefully contribute to a more adequate management of hyperuricemia in gout.